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γ-Aminobutyric acid (GABA), the main inhibitory neurotransmitter in the adult brain, early
in postnatal life exerts a depolarizing and excitatory action. This depends on accumulation
of chloride inside the cell via the cation–chloride importer NKCC1, being the expression of
the chloride exporter KCC2 very low at birth. The developmentally regulated expression of
KCC2 results in extrusion of chloride with age and a shift of GABA from the depolarizing to
the hyperpolarizing direction.The depolarizing action of GABA leads to intracellular calcium
rise through voltage-dependent calcium channels and/or N -methyl-D-aspartate receptors.
GABA-mediated calcium signals regulate a variety of developmental processes from cell
proliferation migration, differentiation, synapse maturation, and neuronal wiring.Therefore,
it is not surprising that some forms of neuro-developmental disorders such as autism
spectrum disorders (ASDs) are associated with alterations of GABAergic signaling and
impairment of the excitatory/inhibitory balance in selective neuronal circuits. In this review,
we will discuss how changes of GABAA-mediated neurotransmission affect several forms
of ASDs including the Fragile X, the Angelman, and Rett syndromes.Then, we will describe
various animal models of ASDs with GABAergic dysfunctions, highlighting their behav-
ioral deficits and the possibility to rescue them by targeting selective components of the
GABAergic synapse. In particular, we will discuss how in some cases, reverting the polarity
of GABA responses from the depolarizing to the hyperpolarizing direction with the diuretic
bumetanide, a selective blocker of NKCC1, may have beneficial effects on ASDs, thus
opening new therapeutic perspectives for the treatment of these devastating disorders.
Keywords: autism spectrum disorders, GABA receptors, bumetanide, neuro-developmental disorders, excitatory
inhibitory balance
Autism comprises a heterogeneous group of neuro-developmental
disorders known as autism spectrum disorders (ASDs) character-
ized by deficits in verbal and non-verbal communication, social
interaction, restricted interests, and stereotyped behavior (1).
The incidence of ASDs (20–60/10000 children) has dramatically
increased over the past decades because of the improvement of
diagnostic criteria and increased attention of medical community
(2). Complications arising from later age pregnancies and from
excessive exposure of fetuses with a genetic vulnerable background
to environmental factors (i.e., toxic agents) may also contribute to
the higher incidence of these disorders in recent years.
In spite different etiologies, ASDs share overlapping symptoms,
indicating common deficits in some neuro-developmental path-
ways. One of these involves the γ-aminobutyric acid (GABA)A-
mediated neurotransmission, known to play a crucial role in
synaptic tuning and neuronal wiring in late pre and early post-
natal days (3). Studies from animal models of ASDs indicate that
a dysfunction in GABAergic signaling within particular neuronal
circuits may account for most of the clinical symptoms found in
autistic patients. The high co-morbidity of ASDs with epilepsy
(30% of cases) further confirms this issue (4).
γ-Aminobutyric acid is the main inhibitory neurotransmit-
ter in the adult mammalian brain. It inhibits neuronal firing by
activating two different classes of receptors, GABAA and GABAB.
GABAA receptors are integral ion channels while GABAB recep-
tors are coupled to ion channels via guanine nucleotide-binding
proteins and second messengers. The opening of GABAA receptors
causes a net influx of chloride with consequent membrane hyper-
polarization and reduction of cell firing. However, in particular
conditions and during brain maturation the intracellular chloride
concentration [Cl−]i rises in such a way that the opening of anion
channels by GABA produces a chloride efflux and a membrane
depolarization that through the activation of a persistent non-
inactivating sodium conductance (5) may reach the threshold for
action potential generation (6, 7). Generally, low [Cl−]i facili-
tates GABA-mediated inhibition, whereas high [Cl−]i facilitates
GABA-mediated excitation. The mechanisms underlying chloride
accumulation inside immature neurons, start to be unveiled with
a different efficacy of chloride co-transporters such as NKCC1 and
KCC2, which import and export chloride, respectively. Before and
immediately after birth, chloride accumulates inside the cell due
to a reduced expression of the cation–chloride exporter KCC2.
Later in development, the intracellular chloride concentration
decreases thanks to the up-regulation of KCC2 (8–10). GABA-
induced membrane depolarization facilitates calcium entry via
voltage-dependent calcium channels and N -methyl-d-aspartate
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(NMDA) receptors. Calcium rise leads to the activation of second
messengers involved in a variety of developmental processes from
cell migration and differentiation to synaptogenesis and circuit
formation (11).
How GABA orchestrates these processes has been extensively
reported (3, 12–14). GABAergic signals operate with multiple
modalities at different developmental stages before glutamatergic
ones (15). At the beginning, GABA works as a trophic factor, mod-
ulating neuronal migration and maturation (16). GABA receptors
are expressed in neuronal progenitors before the establishment of
synaptic contacts (17). At this stage, the receptors work as sen-
sors for GABA present in the extracellular space after its release
in a calcium- and SNARE-independent way from growth cones
and astrocytes (18). The absence of an efficient uptake system
enables this neurotransmitter to accumulate in the extracellular
space and to reach a concentration sufficient to exert its depo-
larizing and excitatory effects on distal neurons. Blocking the
depolarizing action in utero heavily affects migration and circuit
formation (11, 19, 20).
At later developmental stages, when synapses are formed, the
release of GABA and glutamate, generate a primitive form of
network-driven oscillatory events known as giant depolarizing
potentials (GDPs). GDPs are characterized by recurrent mem-
brane depolarizations (lasting several hundred of milliseconds)
that give rise to bursts of action potentials, separated by qui-
escent periods. This network activity thought to be the in vitro
counterpart of “sharp waves” recorded in pups during immobil-
ity periods, sleep, and feeding (21), is reminiscent of the “trace
discontinue” first described by Dreyfus-Brisac in the electroen-
cephalogram of immature babies and characterized by intermit-
tent bursts separated by periods of virtually complete suppression
of activity (22).
In analogy with the synchronized activity generated in the
disinhibited hippocampus by GABAA receptor antagonists (23),
GDPs emerge when a sufficient number of cells fire and the
excitability of the network attains a certain threshold within a
restricted temporal window (24). Although the entire hippocam-
pus possesses the capacity to generate GDPs, for its extensive
glutamatergic connections via recurrent collaterals, the CA3 area
is particularly well equipped to generate synchronized activity.
Furthermore, this area is able to initiate, upon membrane depo-
larization, intrinsic bursts which, by virtue of their spontaneous
discharges and large spike output can drive other neurons to fire
(25, 26). Burst firing is facilitated by a persistent slow sodium cur-
rent (27) and by a tonic GABAA-mediated conductance generated
by the activation of extrasynaptic GABAA receptors by “ambient”
GABA whose depolarizing action would bring the membrane to
the voltage window for activation of voltage-dependent sodium
and calcium channels (28). Intrinsic bursting activity is boosted
by the low expression of Kv7.2 and Kv7.3 channels responsible
for the non-inactivating, low-threshold M current (IM), which in
adulthood controls spike after-depolarization and burst genera-
tion (29). The low density of IM at birth contributes to produce
intrinsic bursts that, in comparison with those observed in adults,
are more robust, last longer and recur more regularly (25). GDPs-
associated calcium transients act as coincident detector signals
for enhancing synaptic efficacy at emerging GABAergic (30) and
glutamatergic synapses (31). Therefore, this early synchronized
activity is fundamental for synaptic wiring and refinement of local
neuronal circuits according to the Hebbian rule that “neurons that
fire together wire together.”
γ-Aminobutyric acid is released from GABAergic interneurons
that constitute a very heterogeneous group of cells, differentially
classified according to their morphology, biophysical properties,
molecular expression profile, and connectivity (32). These cells,
mainly derived from the medial and caudal ganglionic eminences,
undergo their final mitosis in these regions prior to their tangential
migration into the cortical plate. The migration process, supposed
to be calcium dependent, is regulated by a sequence of well-
orchestrated processes involving guidance cues, neurotransmit-
ter receptors (NMDA, GABAA receptors) and voltage-dependent
calcium channels (33, 34).
GABAergic interneurons not only exert a powerful control on
network excitability but, in spite of their relatively low number
(10–15% of the entire neuronal population), are able to synchro-
nize a large number of principal cells giving rise to coherent oscil-
lations, which support different behavioral states of the animals
and high cognitive tasks (35).
Altogether, these observations point to GABA as one of the
major players in the early assembly and formation of neuronal
circuits in the developing brain. Therefore, it is not surprising
that dysfunctions of GABAergic circuits have been implicated in
various neuro-developmental and psychiatric disorders such as
schizophrenia, autism, and epilepsy.
GABAergic DYSFUNCTIONS IN THE BRAIN OF ASD PATIENTS
The high frequency of epileptiform activity and the altered brain
rhythms detected in the EEG of ASDs patients suggest a dys-
function of GABAergic transmission and an imbalance between
excitation and inhibition (E/I) in local circuits involved in sensory,
mnemonic, social, and emotional processes. However, as summa-
rized in Table 1, more direct evidence in favor of a GABAergic
dysfunction in ASDs derives from:
a. Genetic observations
b. In vitro analysis of post-mortem brain tissues
c. In vivo studies on patients affected mainly by idiopathic forms
of ASDs.
It is clear from the Table 1 that most of cases are from juve-
nile and adult patients. This can be attributed to difficulties in
obtained post-mortem material from young children and to per-
form complex in vivo examinations such as positron emission
tomography (PET) and single photon emission computed tomog-
raphy (SPECT) in children of pediatric age. However, we cannot
exclude that the same alterations are already present at early stages
of development.
GENETIC OBSERVATIONS
The involvement of GABAA receptors in ASDs was provided by
genetic studies that have revealed submicroscopic abnormalities
known as “copy-number variations” in chromosomal loci 15q11–
q13, which contains a number of genes encoding for GABAA
receptor subunits (54). These loci can be affected either directly by
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Table 1 | Alterations of GABAergic signaling in patients with idiopathic forms of autism and Rett syndrome.
Clinical phenotype Alterations of GABAergic signaling Age (years) Reference
GENETIC OBSERVATIONS
Idiopathic autism Linkage disequilibrium in GABRB3 7.6±6.2 (36, 37)
Idiopathic autism Altered gene expression in interneurons Not specified (38)
INVITRO ANALYSIS OF POST-MORTEM BRAINTISSUES
Idiopathic autism Reduction in the density of GABAA, GABAB receptors and benzodiazepine binding sites in
the anterior cingulate cortex
19/43 (39)
Idiopathic autism Reduction in the density of GABAB receptors cingulate cortex and fusiform gyrus 19/43 (40)
Idiopathic autism Reduction in 3[H]flunitrazepam labeled benzodiazepines binding sites in the hippocampus 16/22 (41)
Idiopathic autism Decreased number of GABAergic Purkinje cells in cerebellum 13/54 (42)
Idiopathic autism Reduced level of GAD65 and GAD67 in Purkinje cells of cerebellar and parietal cortices 19/30 (43)
Idiopathic autism Decreased GAD67 mRNA levels in cerebellar Purkinje cells 16/30 (44)
Idiopathic autism Decreased GAD65 mRNA levels in cerebellar dentate nuclei 16/30 (45)
Idiopathic autism Increased expression of GABAergic interneurons expressing calcium-binding proteins in
the hippocampus
13/63 (46)
Rett syndrome Disruption in the inhibitory architecture of the cell mini-columns 14.4±4 (47)
INVIVO STUDIES
Idiopathic autism Reduction of GABA concentration in the frontal lobe 2/12 (48)
Idiopathic autism Reduced GABA levels in the perisylvian region of the left hemisphere 12.4±5.2 (49)
Idiopathic autism Reduced expression of GABAA receptors in the superior and medial frontal cortex 7.3±3.5 (50)
Rett syndrome Reduced GABAA receptor density in fronto-temporal cortex 27/41 (51)
Idiopathic autism Significant reduction of α5 GABAA receptor subunits in limbic areas 34/43 (52)
Rett syndrome Reduced KCC2/NKCC1 ratio in the cerebrospinal fluid 0/19 (53)
Numbers refer to mean (usually±SEM) or range values.
single point mutations or indirectly by epigenetic factors. Potential
gene targets include GABRB3, GABRA5, and GABRG3, encoding
for β3, α5, and γ3 subunits containing GABAA receptors, respec-
tively (36, 37). Systematic changes in GABAA receptor subunit
expression were found in the superior frontal cortex, parietal cor-
tex, and cerebellum of autistic subjects. In addition, autism-related
genes have been found to be expressed mainly in GABAergic
interneurons (38).
IN VITRO ANALYSIS OF POST-MORTEM BRAIN TISSUES
Post-mortem analysis on brain tissues from ASD patients as well
as genetic and in vivo studies have largely contributed to unveil the
impact of GABAergic signaling in these disorders. Thus, as com-
pared to controls, a significant reduction in the density of GABAA,
GABAB receptors, and benzodiazepine binding sites was detected
in the supra and infragranular layers of the anterior cingulate
cortex (known to participate in a variety of processes including
socio-emotional behavior and other associative functions via pre-
frontal cortex connectivity) in brain samples from autistic subjects
(39, 40). A reduction of 3[H]muscimol labeled GABAA receptors
and 3[H]flunitrazepam labeled benzodiazepines binding sites was
found also in the hippocampus (41,55). Neuropathological studies
from the cerebellum of individuals with ASDs have demonstrated
that GABAergic Purkinje cells are particularly vulnerable since
their number appears considerably reduced respect to controls
(42, 56, 57). This effect was found to be associated with reduced
levels of mRNA encoding for glutamic acid decarboxylase (GAD)
65 and 67, rate limiting enzymes responsible for the conversion
of glutamate to GABA (43–45, 58). In contrast with Purkinje
cells, enhanced levels of mRNA for GAD67 were found in stel-
late cells, a subtype of interneuron innervating Purkinje cells (43).
Interestingly, pathological studies of brains of individual affected
by autism demonstrated an increased expression of GABAer-
gic interneurons expressing calcium-binding proteins such as
calbindin-, calretinin-, and parvalbumin in the hippocampal for-
mation (46). Since these interneurons are capable of buffering
calcium, the intracellular messenger that controls several trans-
duction pathways, an alteration of calcium signaling may have
dramatic consequences on neuronal functions and dynamics.
Abnormalities in micro-columnar organization of prefrontal
cortex in brain tissues from autistic individuals, including two
with Angelman syndrome, have been also detected (59, 60).
The narrower size of mini-columns in autistic patients respect
to controls may reflect defects in GABAergic fibers within and
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between cortical mini-columns due to reductions in the neuropil,
which separates adjacent mini-columns (47). This may alter local
connectivity and lateral inhibition.
IN VIVO STUDIES ON PATIENTS AFFECTED MAINLY BY IDIOPATHIC
FORMS OF ASDs
In vivo studies from ASD patients are rather limited due to the
difficulty of measuring GABAergic function in vivo. Using proton
magnetic resonance spectroscopy, Harada et al. (48) reported a
reduction of GABA concentration in the frontal lobe of children
with ASDs respect to controls. However, in this study ASD patients
were sedated with triclofos a compound that, by potentiating
GABA action, may have biased the results. Using the same tech-
nique, Rojas et al. (49) have reported reduced GABA levels in the
perisylvian region of the left hemisphere of autistic patients, fur-
ther supporting the involvement of GABAergic neurotransmission
in ASDs. Using SPECT and 123I-iomazenil, a selective GABAA-
benzodiazepine ligand, a reduced expression of GABAA receptors
in the superior and medial frontal cortex of autistic patients was
detected (50). Using the same technique, a reduced GABAA recep-
tor density was observed in three adult females affected by the
Rett syndrome (51). In addition, a pilot study using PET and
[11C]Ro15-4513 to measure the expression levels of α5 GABAA
receptor subunits (localized mainly to extrasynaptic regions where
they mediate tonic inhibition), has demonstrated a significant
reduction of these subunits in limbic areas of ASD patients respect
to controls (52).
Indirect evidence for deficits of GABAergic transmission in
ASDs was provided by a recent magneto-encephalographic study
that revealed impaired gamma-band activity in selective brain
areas of adults with autism during perceptual visual process-
ing (61). Gamma-band oscillations known to critically depend
on negative feedback inhibition of principal cells by GABAer-
gic interneurons, including parvalbumin-positive ones (62), are
crucial for integrating multisensory information into a coherent
representation (63). Although no data from young ASD patients
are available, the possibility that such impairment may result from
aberrant pre and perinatal development cannot be excluded.
Although informative, these studies referred mainly to idio-
pathic forms of ASDs and failed to address whether particu-
lar types of autistic syndromes, including monogenic ones were
similarly affected. In this perspective, it is worth noting that a
significant reduction of the cation–chloride importer KCC2 in
the cerebrospinal fluid of Rett syndrome patients as compared
to controls, with a consequent reduction in the KCC2/NKCC1
ratio was found (53). In accord with the notion that the methyl-
CpG-binding protein 2 (MeCP2), encoded by the X-linked Mecp2
gene, is highly expressed in GABAergic interneurons where it reg-
ulates their function these data suggest that a GABA dysfunction
underlies the pathophysiology of the Rett syndrome.
Altogether, these findings indicate that alterations of GABAer-
gic signaling in selective microcircuits of well-defined brain areas
exert a fundamental role in the pathogenesis of ASDs.
GABAergic DYSFUNCTIONS IN ANIMAL MODELS OF ASDs
Over the last decade several animal models of ASDs have been gen-
erated, in order to identify the molecular and cellular mechanisms
underlying these disorders and to develop new therapeutic tools.
To this aim, genetic defects detected in patients with ASDs have
been introduced in the genome of mice. Animal models have
been produced not only by manipulating candidate genes but also
environmental factors or drugs such as valproic acid (VPA), an
antiepileptic known to be a risk factor for autism in offspring of
mothers treated during pregnancy with this drug (64). In accor-
dance with human observations, animal studies have revealed
important dysfunctions in GABAergic signaling occurring at
different locations of the GABAergic synapse (Figure 1).
Table 2 summarizes alterations of GABAergic transmission
observed in the most commonly used animal models of ASDs.
The Fragile X syndrome is a monogenetic disorder caused by
mutations of the FMR1 gene, located in chromosome X (Xq27.3)
and encoding for theFragileX mental retardation protein (FMRP),
which is involved in the translation of a variety of mRNAs. Gene
mutations do not allow the expression of the FMRP protein, deter-
mining a phenotype characterized by intellectual disabilities asso-
ciated with language deficits, hyperactivity, autistic behavior, and
seizures (85). Mice lacking the FMR1 gene (Fmr1 KO mice) show
an increased network excitability associated with an E/I imbalance
in cortical circuits involving specific types of interneurons (65, 67,
86, 87). Thus, in the somatosensory cortex, the reduced activity
of parvalbumin-positive cells (66) may contribute to enhance cell
excitability and to affect gamma frequency oscillations, thought
to be involved in high cognitive functions (86). The enhanced
coupling of group I metabotropic glutamate receptors (mGluR)
signaling and cannabinoid receptors mobilization may further
enhance suppression of inhibition (88). Other factors contribut-
ing to enhance cell excitability include: (i) a reduced expression
of GABAA receptors subunits in the cortex. This may represent
an evolutionary conserved hallmark of the Fragile X syndrome
since similar reduction has been detected in the Fragile X fruit
fly model (89). (ii) A down regulation of mRNA encoding for
GAD65 and GAD67 in presynaptic terminals of the cortex and
cerebellum; (iii) a reduction of mRNA encoding for gephyrin,
the scaffold molecule responsible for glycine and GABAA recep-
tor clustering and stabilization at post-synaptic sites; (iv) reduced
phasic and tonic GABAA-mediated conductances in the amygdale
associated with a down regulation of GABAA receptor subunits
(65, 68, 89); (v) a down regulation of GABAA-mediated tonic inhi-
bition associated with a reduced expression of α5 and δ GABAA
receptors subunits in subicular neurons (69). In contrast, electro-
physiological recordings from the striatum of Fmr1 KO mice have
revealed a selective increase in basal inhibitory neurotransmission,
caused by the enhanced probability of GABA release (90). Over-
all these data suggest that in this animal model modifications of
the GABAergic function are region-specific. Interestingly, a recent
study from the hippocampus of mice carrying the Fragile X muta-
tion, has revealed the loss of oxytocin-mediated GABAA-mediated
inhibition during the delivery process (70). In rats, oxytocin, the
maternal hormone involved in delivery, has been shown to cause
an abrupt shift of GABA from the depolarizing to the hyperpo-
larizing direction, thus exerting a neuroprotective and analgesic
action on newborns (91). Unlike wild-type animals, the depolar-
izing action of GABA, apparently caused by the reduced expression
of KCC2 with consequent high [Cl−]i, persists in juvenile life. The
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FIGURE 1 | GABAergic synapse. (A) Pre and post-synaptic sites of the synapse with different components whose functions can be altered in ASDs.
(B) Direction of GABA action (depolarizing and hyperpolarizing) in immature and mature neurons.
increased excitatory drive to principal cells boosts network activity
in the hippocampus, suggesting that an altered E/I balance may be
caused not only by a decreased GABAA-mediated inhibition but
also by an enhanced GABAA-mediated excitation (70).
Another neuro-developmental disorder showing high co-
morbidity with autism is the Rett syndrome. This is caused by
mutations in the X-linked Mecp2 gene that codes for the tran-
scriptional factor MeCP2, highly expressed in GABAergic neurons
(92). This disorder affects mainly girls who develop normally until
the age of 6/18 months. Later, they develop cognitive deficits, loss
of speech, motor abnormalities, respiratory dysrhythmias, stereo-
typed behavior, and seizures leading sometimes to premature
death (93). Mice lacking MeCP2 or engineered to express an allele
mimicking some mutation present in the Rett syndrome exhibit
neurological symptoms reminiscent of those found in patients
affected by the Rett syndrome. Similarly to Fmr1 KO mice, these
animals exhibit alterations of the E/I balance (71), associated with a
decrease in somatic GABA content and low levels of mRNA encod-
ing for GAD65 and GAD67 in cortical and striatal neurons (75).
While in the thalamus, the Mecp2 gene appears to differentially
regulate the development of GABAergic synapses in excitatory and
inhibitory neurons (94), in the brain stem, the E/I imbalance is due
to the depression of GABAergic transmission originating at both
pre- and post-synaptic levels (72). A reduced GABAergic inhibi-
tion is present also in the locus coeruleus (73). In the hippocampus
of Mecp2 KO mice, a significant reduction in the quantal size of
miniature inhibitory post-synaptic currents (mIPSCs) has been
detected. This would account for the impairment of long-term
potentiation (LTP) induced at CA3–CA1 synapses by theta burst
stimulation (74).
An E/I imbalance has been found also in individuals with
Tuberous sclerosis, a genetic multisystem disorder characterized
by wide spread hamartomas in several organs, including brain,
heart, skin, eyes, kidney, lung, and liver (95). Tuberous sclerosis
patients exhibit a variety of neurological disorders including men-
tal retardation, autism-like disorders, and epilepsy. The affected
genes are Tsc1 and Tsc2 encoding hamartin and tuberin, respec-
tively. The hamartin–tuberin complex inhibits the mammalian
target of rapamycin pathway that controls cell growth and prolif-
eration (95). Immunocytochemical and western blots experiments
have demonstrated that this disorder is associated with a decrease
of α1 GABAA receptor subunits and reduced and enhanced lev-
els of KCC2 and NKCC1, respectively, in tubers. Changes in the
expression of KCC2 and NKCC1 account for the excitatory action
of GABA revealed with patch clamp in slices fromTuberous sclerosis
tubers (96). However, electrophysiological data are still prelimi-
nary and should be taken with caution since they refer only to
experiments from cortical slices obtained from tubers of a single
patient. The Angelman or the closely related Prader–Willi syn-
dromes (depending from which parent the deletion has been
inherited), characterized by mental retardation, autistic behav-
ior, and seizures, are determined by the loss of function of the
Ube3a gene encoding for the a ubiquitin E3 ligase or Gabrb3,
Gabra5, and Gabrg3 genes, encoding, respectively for β3, α5, and
γ3 GABAA receptor subunits localized in the same chromosome
region 15q11–q13. Ube3a-deficient mice exhibit a reduced tonic
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Table 2 | Alterations of GABAergic signaling in animal models of ASDs (E, embryonic day; P, postnatal day).
Animal models Alterations of GABAergic signaling Age Reference
Fmr1 KO (X Fragile) Reduced GABA release in the amygdala P20–30 (65)
Reduced number of parvalbumin-positive interneurons Adult (66)
Altered E/I balance P14–P30 (67)
Decreased expression of GAD67 and GABAA receptor subunits Adult (68)
Down regulation of GABAA-mediated tonic inhibition Adult (69)
Persistent depolarizing effect of GABA in juvenile animals E20–P30 (70)
MECP2 KO (Rett syndrome) Altered E/I balance P14–P35 (71)
Depressed GABAergic synaptic transmission P7 (72)
P14–P28 (73)
Adult (74)
Reduced expression of GAD65 and GAD 67 Adult (75)
Ube3a-deficient mouse (Angelman
syndrome)
Reduced GABAA-mediated tonic inhibition P25–P28
or adult
(76)
GABRB3 KO (Angelman syndrome) Decreased expression of GABAA receptors Adult (77)
Scn1a+/− mice (Dravet’s syndrome) Altered E/I balance P21–P30 (78)
NL3R451CKI Increased GABAergic neurotransmission; increased VGAT and gephyrin expression P13–P16 (79)
Increased frequency of GDPs P4–P35 (14)
Circuit specific changes in GABAergic signaling in the hippocampus and in the cortex P21–P35 (80)
P9–P15 (81)
Decreased number of PV+ interneurons P21–P35 (82)
En2 KO Reduction of GABAergic markers during development; reduced number of
GABAergic interneurons
Adult (83)
VPA model Decreased GABAA-mediated neurotransmission P23–P45 (84)
Persistent depolarizing effect of GABA in juvenile animals E20–P30 (70)
GABA-mediated inhibition in the cerebellum, caused by a GAT-1
dependent decrease of GABA concentration in the extracellular
space (76). Moreover, β3-deficient mice, which have a pheno-
type similar to some forms of Angelman syndrome, exhibit a
reduced expression of GABAA receptors in selective brain regions
as determined by quantitative autoradiography (77).
The Dravet’s syndrome is caused by a haploinsufficiency
of the SCN1A gene encoding for voltage-gated sodium chan-
nel NaV1.1. Children affected by this disorder show intractable
seizures, cognitive deficit, and autism spectrum behaviors. GABA
plays a pivotal role also in this disorder as demonstrated by
the reduced activity of NaV1.1 channels in forebrain GABAer-
gic interneurons of Scn1a+/− mice. These animals exhibited an
E/I imbalance resulting from a decreased frequency of sponta-
neous inhibitory post-synaptic currents and an increased fre-
quency of spontaneous excitatory post-synaptic currents in the
hippocampus and prefrontal cortex. The impairment of GABAer-
gic neurotransmission is associated with behavioral and cognitive
deficits similar to those found in patients affected by the Dravet’s
syndrome (78).
Although rare, single mutations of genes encoding for adhesion
molecules of the Neuroligin (NL) family found in individuals with
autism have been introduced in mice. One of these, the R451C
mutation of the Nlgn3 gene encoding for NL3, has been found
in a family with children affected by ASDs (97). NLs are adhe-
sion post-synaptic proteins that, by binding to their presynaptic
partners, neurexins, functionally couple the post-synaptic densi-
ties with the transmitter release machinery, thus contributing to
synapses stabilization (98). Mice carrying the NL3 R451C muta-
tion (NL3R451C knock-in mice) show modifications of GABAergic
signaling associated with behavioral deficits reminiscent of those
found in autistic children (79, 99). These mice exhibit an increased
frequency of mIPSCs in the somatosensory cortex (79) and in
the CA3 region of the hippocampus (100) where they contribute
to boost GDPs activity. A more detailed analysis of GABAer-
gic microcircuits in the hippocampus has unveiled an increased
GABA release at synapses between cholecystokinin (CCK)-positive
endocannabinoids-sensitive interneurons and pyramidal cells and
a decreased GABA release at synapses between parvalbumin-
positive basket cells and principal cells (80). The similar phenotype
found at CCK–pyramidal cell synapses in NL3R451C knock in mice
and in NL3 KO mice suggests a loss of function consisting in the
loss of tonic endocannabinoid signaling at these connections. It is
worth noting that NL3R451C knock-in mice present an asymmet-
ric reduction of parvalbumin-positive basket cells across the two
hemispheres (82).
Similarly to Földy et al. (80), a reduced probability of GABA
release has been found in parvalbumin-positive basket cell–spiny
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neuron synapses in layer IV somatosensory barrel cortex of juve-
nile NL3R451C knock in mice. Such deficit determines an alteration
of the E/I balance in this cortical layer together with a modification
of the temporal window for integration of sensory inputs in prin-
cipal cells (81). The altered sensory representations may underline
deficits in coherent percepts of autistic children.
Mutations in the En2 gene, coding for the homeobox-
containing transcription factor engrailed-2 (EN2), involved in pat-
terning and neuronal differentiation of the midbrain/hindbrain
region, have been associated with ASDs. En2 KO mice have been
proposed as a model for ASDs due to their behavioral abnormal-
ities similar to those observed in individuals with ASDs (101).
The En2 gene is also involved in the development or mainte-
nance of GABAergic interneurons as demonstrated by the selective
loss of parvalbumin, somatostatin, and neuropeptide Y positive
interneurons in the cortex and hippocampus of En2 KO mice (83).
This effect appears to be region-specific since different subpopu-
lations of interneurons are affected in posterior brain areas (102).
Deficits in GABAergic neurotransmission account for the higher
susceptibility to seizures of En2 KO mice respect to controls (103).
Valproic acid is a histone deacetylase inhibitor, widely used to
cure epilepsy and bipolar disorders. VPA is also a potent teratogen
since children exposed in utero to this drug have a much higher risk
of developing an autistic-type behavior than normal children (64).
Pups exposed to VPA in utero show neuro-developmental abnor-
malities and behavioral deficits similar to ASDs (104). As in other
animal models of ASDs, the autistic phenotype is associated to an
altered E/I balance due to a decreased GABAergic signaling, which
affects both pre- and post-synaptic sites, leaving the extrasynap-
tic transmission unaffected (84). Interestingly, like the NL3 model,
the VPA model exhibits an asymmetric reduction of parvalbumin-
positive cells across the two hemispheres (82). Similarly to FRM1
KO mice, also in this animal model a loss of oxytocin-mediated
GABAA-mediated inhibition occurs during the transition from
fetal to postnatal life (70). Also here as in Fmr1 KO mice, the
depolarizing action of GABA in the hippocampus persists in juve-
nile life. The excitatory GABAergic drive to principal cells leads to
an increased network activity in a broad spectrum of frequencies
including gamma oscillations.
The different animal models mentioned here have in common
dysfunctions of GABAergic signaling leading to alterations of the
E/I balance in selective brain circuits. These alterations can be
rescued by selective tools that regulate GABAA-mediated synaptic
transmission.
THERAPEUTIC INTERVENTIONS TO RESCUE GABAergic
DYSFUNCTIONS IN ASDs
Figure 1 shows a GABAergic synapse with its different con-
stituents.
As summarized in Figure 1A, GABA released from a presy-
naptic terminal binds to post-synaptic GABAA receptors localized
on precise apposition to presynaptic release sites. It binds also to
presynaptic and post-synaptic GABAA and GABAB receptors [for
a review see Ref. (105)]. Post-synaptic GABAB receptors are local-
ized mainly at perisynaptic sites. Post-synaptic GABAA receptors
are maintained in the right place by gephyrin, a scaffold pro-
tein which, by interacting with cytoskeletal anchoring elements,
contributes to regulate receptor trafficking in and out of the
synapses (106). Before being released in a calcium-dependent way,
GABA is synthesized by GAD65 and GAD67 and it is stored in
presynaptic vesicles by the vesicular transporter VGAT, which uses
the electrochemical gradient for H+ to shuffle and pack GABA into
synaptic vesicles (107). The probability of GABA release is under
control of presynaptic receptors including GABAA and GABAB
receptors. Adhesion molecules of the neuroligin–neurexin fami-
lies ensure the cross-talk between post and presynaptic elements
of the synapses (98). The figure also shows that the presynaptic
terminal contains sodium channels, since, as already mentioned,
a selective mutation of these channels in GABAergic interneurons
of the forebrain is responsible for the Dravet’s syndrome. After
being released, GABA is taken up into nerve terminals and astro-
cytes by GABA transporters (GATs) localized on presynaptic nerve
terminals and astrocytes.
Figure 1B shows the direction of chloride fluxes through post-
synaptic GABAA receptors in immature and mature neurons. The
influx or efflux of chloride in and out of the cells is mainly dictated
by the activity of two developmentally regulated cation–chloride
co-transporters, the NKCC1 and KCC2, which pump chloride
inside and outside of neurons, respectively (8). Therefore, dif-
ferent components of the synapses can be selectively targeted by
agents that can rescue their functions.
Due to the co-morbidity of ASDs with epilepsy, anticonvulsants
are widely used for the symptomatic treatment of these disor-
ders (108). Some of these drugs have also an anti-anxiety effect
and may indirectly increase GABAA neurotransmission by pro-
moting the synthesis of GABA or by inhibiting their reuptake or
breakdown. Interestingly, treatment with vigabatrin, which blocks
GABA catabolism by inhibiting GABA transaminase, is able to
control seizures and to improve the autistic behavior of children
affected by tuberous sclerosis (109).
γ-Aminobutyric acid agonists have proved to be effective in
normalizing the E/I imbalance in animal models of Autism: they
can either directly enhance inhibition or indirectly reduce excita-
tion. Thus, in BTBR mice [an animal model of idiopathic autism,
Ref. (110)] or in Scn1a+/−mice [a monogenic model of ASDs, Ref.
(78)], in which a reduced GABAA-mediated inhibition occurs, the
treatment with low non-sedative, non-anxiolytic doses of benzodi-
azepines, or clonazepam, known to enhance GABAergic signaling
via allosteric modulation of post-synaptic GABAA receptors, leads
to an improvement of social and cognitive deficits. Interestingly,
in both BTBR and Scn1a+/− mice, the up-regulation of α2 and/or
α3 containing GABAA receptors subunits by L-838,417, a selec-
tive positive allosteric modulator of these subunits, which does
not induce tolerance, is able to mimic the effects of benzodi-
azepines, thus providing an attractive tool to enhance GABAergic
neurotransmission and to improve behavioral deficits in ASDs
(110). Consistent with this view, clinical trials using α2/α3 selec-
tive positive allosteric modulators of GABAA receptors have been
developed with AstraZeneca and the National Institutes of Health
(http://clinicaltrials.gov/show/NCT01966679).
Animal models of the Rett syndrome are currently used
in translational studies for the preclinical evaluation of new
therapeutic trials (111). Genetic studies have provided evidence
that neuronal dysfunctions and autistic symptoms can be reversed
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upon restoration of MeCP2 protein in mice in which the Mecp2
gene has been silenced using a lox-Stop-lox cassette (112, 113),
suggesting that in this animal model, the neuronal connectivity is
not altered and neurons and glia are not permanently damaged
by the Mecp2 loss. Pharmacological studies have demonstrated
amelioration of autistic symptoms with IGF-1 (114) or BDNF
(115). However, since most of autistic features of the Rett syn-
drome can be recapitulated by deleting the Mecp2 gene in GABA
releasing neurons (75), these are expected to be rescued by drugs
that enhance GABAergic neurotransmission.
Treatment of Fmr1 KO mice (an animal model of Fragile X
syndrome), exhibiting an hyper-excitability and a GABAergic dys-
function in the basolateral nucleus of the amygdala, with gabox-
adol (THIP), a selective agonist at δ subunits containing perisy-
naptic or extrasynaptic GABAA receptors, results in an increased
GABAA-mediated tonic conductance and in beneficial effects on
learning deficits and behavioral disturbances linked to this dis-
order. This supports the hypothesis that tonic inhibition is a
putative target for the treatment of Fragile X syndrome (65, 116).
In addition, consistent with the notion that mGluR are important
regulators of protein synthesis, which is translationally repressed
by the FMR protein, partial inhibition of mGluR5 or inhibition of
excessive glutamate release by the GABAB receptor agonist arba-
clofen in Fmr1 KO mice have led to promising results (117, 118).
Although the selective activation of GABAB receptors with arba-
clofen has the potential to improve social function and behavior
in patients with Fragile X syndrome (119), its use in clinical trials
is still under debate (120).
It is worth mentioning that in some children affected by
ASDs, allosteric modulators of GABAA receptors such as benzodi-
azepines have a paradoxical effect, increasing anxiety, and aggres-
sion (121). Therefore, restoring low [Cl−]i and the inhibitory
action of GABA, using the selective blocker of the NKCC1 chloride
importer bumetanide, may have beneficial effects. In an elegant
study, Tyzio et al. (70) have convincingly demonstrated that, treat-
ing pregnant VPA rats and Fragile X mice shortly before delivery
with bumetanide, suppresses in both animal models the exci-
tatory action of GABA and prevents the autistic-like behavior
in off springs. Bumetanide may not only reverse GABA action
from the depolarizing to the hyperpolarizing direction, but it
may also reduce cell excitability by an ephaptic type of mech-
anism involving regulation of the cell volume and the extracel-
lular space (122). Animal data validate previous findings by the
same group, showing amelioration of autistic symptoms in chil-
dren treated for 3 months with bumetanide (123, 124). Although
these studies should be expanded to larger multicenter trials
with more restricted inclusion and exclusion criteria and more
extended investigations on the dose/response action of the diuretic
as well as persistence of action after drug’s withdrawal, the sig-
nificant improvement of the autistic behavior associated with
a statistically significant amelioration of childhood autism rat-
ing scale (CARS) and clinical global impressions (CGI) scores
in the absence of clear side effects make this diuretic a very
promising drug to cure ASDs. In a parallel study, bumetanide was
shown to improve accuracy in facial emotional labeling and to
increase brain activation in areas involved in social and emotional
perception (125).
CONCLUSION
Several lines of evidences suggest that ASDs are neuro-
developmental disorders characterized by a clear E/I imbalance
in selective neuronal circuits. Such disequilibrium appears to be
mainly related to heterogeneous defects of GABAergic signaling
in different brain structures. This has paved the way toward the
development of new drugs for the cure of these devastating dis-
orders. In particular, several studies have shown that drugs acting
on GABAergic synapses are able to rescue behavioral deficits in
animal models of autism and to ameliorate at least some of the
symptoms observed in ASD patients.
In order to successfully translate therapeutic approaches from
animal to humans, it is necessary to develop animal models of
ASDs that faithfully trace the behavioral alterations detected in
ASD patients. In addition, the effects of drugs should be validated
in humans in large scale clinical trials with accurate controls.
Since ASDs are developmental disorders, the early pharmaco-
logical intervention, guaranteed by an early diagnosis, is essential.
This means that very young children will receive drugs, whose
side effects have to be carefully considered. For instance, many
drugs acting on GABAergic synapses can generate addiction or
give rise to paradoxical reactions, as brain circuits are still imma-
ture and GABA may still exert a depolarizing and excitatory action
which can be prolonged at late stages of development. Only accu-
rate studies and the use of well suited animal models can help to
design pharmacological tools with minimal risks.
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